Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Akebia Therapeutics, Inc. AKBA

Healthcare  —  Drug Manufacturers Specialty & Generic
0.90 (0.02) (2.17%) as of 25 Sep
Market cap
$254.7M
P/E
0.0×
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio 0.00 0.00 0.00 0.00

+8 more quarters
P/S ratio 1.40 1.60 1.75 3.21
P/FCF ratio 7.63 6.18 6.10 22.35
P/Operating CF 87.19 (17.50) 13.30 25.72
P/B ratio 12.29 13.56 12.70 17.38
Price to Tangible BV 0.00 0.00 0.00 0.00
EV/Sales 0.92 1.11 1.25 2.76
EV/EBITDA 0.00 39.17 11.91 22.17
EV/Operating CF 4.85 4.26 4.34 19.19
EV/FCF 5.00 4.29 4.35 19.22
Quick Ratio 1.30 1.30 1.42 1.74
Current Ratio 1.43 1.40 1.55 1.94
Net Debt/EBITDA 18.46 26.04 16.59 (24.92)
Debt/Assets 14.17% 13.49% 12.81% 13.08%
Debt/Equity 1.98 1.79 1.48 1.15
Asset Turnover 0.63 0.69 0.79 0.79
Operating CF/Net income (0.40) 2.34 (2.54) 52.05
Capex/Depreciation (1.84) (0.19) (0.22) (0.24)
Interest Coverage 0.00 0.00 0.00 0.00
Research and Development Expense of Revenue 28.62% 27.65% 46.25% 25.43%
Selling, General and Administrative Expense of Revenue 57.34% 56.84% 45.28% 49.51%
Intangible Assets out of Total Assets 0.17 0.16 0.16 0.16
Share Based Compensation of Revenue 6.57% 6.85% 5.55% 5.48%
Graham Net Nets (0.31) (0.25) (0.22) (0.09)
Graham Number 0.00 0.00 0.00 0.00
Earnings Yield (9.47%) (5.55%) (1.06%) (2.46%)
Free Cash Flow Yield 13.10% 16.17% 16.39% 4.47%
Revenue per Share 0.18 0.20 0.22 0.22
Operating CF per Share 0.01 (0.08) 0.12 0.11
Capex per Share 0.00 0.00 0.00 0.00
Free Cash Flow per Share 0.01 (0.08) 0.12 0.11
Cash per Share 0.58 0.61 0.72 0.63
Shareholders Equity per Share 0.09 0.10 0.13 0.16
Interest Debt per Share 0.00 0.00 0.00 0.00
Book value per Share 0.09 0.10 0.13 0.16
Free Cash Flow 2.45 (21.27) 31.06 28.03
Working Capital 68.69 69.60 90.02 124.96
Capital Expenditures (1.08) (0.06) (0.07) (0.08)
Net Current Asset Value (95.09) (91.66) (91.00) (64.22)
EV/EBIT 0.00 48.67 12.55 35.03
Capex to Sales 0.02 0.00 0.00 0.00
Net Profit Margin (18.13%) (16.91%) (21.25%) 0.92%
Price to Operating Income 0.00 70.18 17.62 40.73
Other line items
Average Receivables 63.16 62.04 40.70 49.20
Average Payables 10.49 10.52 18.18 11.79
Average Inventory 14.86 16.36 15.93 19.57
Average Assets 347.63 336.35 298.62 285.65
Average Common Equity 27.12 25.98 (8.29) (4.41)

Fold the line items

Columns are period end dates